LSKB’s Lead Project Set For Phase III Gastric Cancer Trial

During an investor relations meeting in Seoul, South Korea’s HLB talked about recent clinical R&D progress for the lead project at its subsidiary LSK BioPharma and its developing pipeline. LSK revealed it is set to begin global Phase III trials for apatinib in gastric cancer and also aims to move on to the clinical development of a newly licensed in BTK inhibitor within 2016.

SEOUL - LSK BioPharma Inc. (LSKB) has completed a Phase IIa clinical trial for its gastric cancer therapy apatinib, a vascular endothelial growth factor receptor-2, or VEGFR-2, inhibitor, in the US and now plans to move into an international Phase III program based on the positive outcome of the study.

The company plans to file for an IND to the US FDA next month and to conduct the Phase III...